ICCM News and Press, IceCure Medical Ltd.

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 PR Newswire Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destr...

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation PR Newswire First procedures to be performed in the coming weeks at Alabama's largest non-governmental healthcare system Purchase ...

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense® PR Newswire ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer Cryoablation for breast cancer is no...

2026-02-09 16:38:01 ET More on IceCure Medical IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript IceCure Medical reports nine months ended results Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical ...

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved PR Newswire Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel , Feb. 9, 2026 /PRNewswire/ --  IceCure Medical Ltd. (Nasdaq: ICCM...

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer PR Newswire ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of ...

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales PR Newswire Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution ...

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer PR Newswire ProSense® systems are being sold and installed at new locations across North America , including some o...

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting PR Newswire Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patie...

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PR Newswire Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic a...